<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014416</url>
  </required_header>
  <id_info>
    <org_study_id>156-KOA-0801</org_study_id>
    <nct_id>NCT01014416</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dose, Dose-escalation Study to Investigate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Tolvaptan in Healthy Korean Male Subjects Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety, tolerance, pharmacokinetics and pharmacodynamics of tolvaptan 15,
      30 and 60 mg after single oral administration in healthy Korean male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters: AUC, Cmax, Tmax</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PD parameters: 24 hour fluid balance</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: adverse event, body weight, physical examination, vital sign, ECG, clinical laboratory test</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Tolvaptan 15mg or Placebo/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Tolvaptan 30mg or Placebo/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Tolvaptan 60mg or Placebo/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan 15mg or 30mg or 60mg or Placebo</intervention_name>
    <description>Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Korean male subjects between 20 and 45 years of age, inclusive.

          2. Body Mass Index (BMI) of 20 to 26 kg/m2, body,weight ≥ 50kg BMI = weight
             (kg)/height2(m)

          3. Informed consent from the subjects

        Exclusion Criteria:

          1. Clinically significant abnormality of respiratory, cardiovascular, hepatic,
             neurologic, endocrine, hematologic, urinary, psychiatric.

          2. History of gastrointestinal disease or surgery which can affect intestinal absorption
             of the study drug.

          3. History of any significant drug allergy or hypersensitivity.

          4. AST or ALT &gt; 1.25 times upper normal limit at screening clinical laboratory test

          5. Supine blood pressure after resting for ≥ 3 minutes, higher than 140/90 mmHg or lower
             than 100/50 mmHg, Supine pulse, after resting for ≥ 3 minutes, outside the range of 40
             to 90 beats/minute.

          6. Subjects who had history of drug abuse or alcohol addiction

          7. Subjects who used of any prescription drug or herbal medication within 2 weeks prior
             to the first dosing of the study drug, or any over-the-counter or vitamin supplements
             within 1 week prior to the first dosing (However, investigators can judge the subject,
             who has taken the medications during those periods above, eligible for the trial if
             all other conditions are satisfied)

          8. The investigator judges the subject not eligible for the study after reviewing
             clinical laboratory results or other reasons.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2009</study_first_submitted>
  <study_first_submitted_qc>November 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <last_update_submitted>March 10, 2010</last_update_submitted>
  <last_update_submitted_qc>March 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>SungWoo Hong</name_title>
    <organization>Korea Otsuka Pharmaceutical Co.,Ltd.</organization>
  </responsible_party>
  <keyword>Healthy Korean male</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

